Mobia Medical, Inc. quarterly report, Q3 FY2026

Mobia Medical, Inc. — Q3 2026 Form 10-Q

Reporting period: Three and nine months ended September 30, 2026; comparisons are with the corresponding 2025 periods. Mobia is a commercial-stage medical-device company focused on its Vivistim Paired Vagus Nerve Stimulation System for chronic ischemic stroke survivors. The company changed its name from MicroTransponder, Inc. in February 2026.

Key financial results

MetricQ3 2026Q3 2025Nine months 2026Nine months 2025
Revenue$15.6 million$9.0 million$41.2 million$21.3 million
Gross profit$13.0 million$7.2 million$34.2 million$17.3 million
Gross margin83.2%79.6%83.0%81.1%
Operating expenses$31.5 million$18.4 million$87.6 million$49.3 million
Operating loss$18.5 million$11.3 million$53.4 million$32.0 million
Net loss$17.3 million$11.4 million$56.1 million$32.6 million
Net loss per share$0.52$13.31$3.14$38.72

Revenue increased 73% in Q3 and 93% year to date, primarily from higher Vivistim adoption and unit sales; management said average selling price remained consistent. Gross margin improved, mainly due to lower inbound freight, tariff costs and inventory write-offs. SG&A rose 72% in Q3 and 80% year to date, reflecting commercial headcount and commissions, share-based compensation, marketing and professional costs. R&D increased with higher headcount and product development activity.

Cash flow and liquidity: Nine-month operating cash use was $46.3 million, versus $32.3 million in 2025; investing cash use was $1.6 million versus $0.3 million. Financing provided $175.1 million, including approximately $134.0 million of IPO net proceeds. Cash and cash equivalents were $160.7 million at September 30, 2026, up from $33.6 million at year-end 2025. Accumulated deficit was $213.9 million. Management expects current cash to fund planned operations and obligations for at least 12 months from issuance of the statements, though it expects continued losses and negative operating cash flow.

Debt and other obligations: The company had $7.5 million of principal outstanding under its Horizon loan (carrying value $7.3 million, net of discounts and costs). The loan is secured by substantially all assets other than intellectual property, bears interest at the greater of 12.25% or prime plus 3.75%, and matures January 2029; interest-only payments run through January 2028. The company reported covenant compliance. Non-cancelable supplier purchase orders totaled approximately $16.8 million, expected to be fulfilled within 12 months. Other disclosed commitments include approximately $5.8 million of minimum purchases under a future supply agreement and $4.6 million for software services over five years.

Material changes and notable items

  • In May 2026, Mobia completed its IPO, selling 10 million shares at $15 per share for approximately $134.0 million net proceeds. Preferred stock converted into 18.8 million common shares, and $40 million of convertible notes converted into approximately 3.3 million common shares. The notes generated a $4.9 million fair-value loss before conversion; none remained outstanding at quarter-end.
  • Common shares outstanding increased from 884,030 at December 31, 2025 to 33,326,104 at September 30, 2026, reflecting the IPO and conversions, among other issuances. The filing also reports a 1-for-3.483 reverse stock split in May 2026, reflected retrospectively in share and per-share data.
  • Interest income on the larger cash balance contributed to Q3 other income of $1.2 million, compared with $0.2 million of other expense in Q3 2025. Year-to-date total other expense was $2.7 million, including the convertible-note fair-value loss.
  • Warranty liability increased to $1.6 million from $0.8 million at year-end 2025. Warranty accruals were higher year over year, partly reflecting increased sales.

Outlook, commentary and risks

Management expects operating expenses to continue increasing as it expands commercial operations, supports awareness and adoption, invests in R&D and clinical evidence, and operates as a public company. The filing provides no quantified revenue or earnings guidance. Management cited July 2026 publication of two-year pivotal-trial follow-up data showing sustained improvements, and an August 2026 AHA/ASA guideline update stating paired vagus nerve stimulation with high-dose, task-specific training may be considered for eligible patients.

Key risks include dependence on Vivistim and on greater physician and patient adoption; payer coverage and prior authorization, including the absence of a national CMS coverage determination; reliance on a small number of third-party suppliers, including contract manufacturers in Uruguay; potential tariffs, trade disruption and supply constraints; and continued operating losses. Management said existing capital removes substantial doubt about going concern for at least one year from issuance, but warns financing may be needed if cash or revenue is insufficient. The company reported no material pending legal proceedings and no material changes to previously disclosed risk factors.

Important facts for investors to verify

  • Whether revenue growth and customer adoption continue, and whether reimbursement access expands or changes.
  • Cash burn, actual runway relative to management’s at-least-12-month estimate, and the pace of commercial and R&D spending.
  • Gross-margin durability amid product warranty costs, tariffs, freight and supplier concentration.
  • Fulfillment and financing implications of the $16.8 million purchase commitments, future supply minimums and service commitments.
  • Potential dilution from outstanding options and awards: 7.2 million options and 287,010 restricted stock units were outstanding at quarter-end; loss-period diluted EPS excludes anti-dilutive securities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.